Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SAFE-Infusion

Financiado

Cerrado

Stop Adverse Fluid Events in Infusion weak link tube connection and air removal...

Stop Adverse Fluid Events in Infusion weak link tube connection and air removal devices for safer more accurate and cost effective IV therapy in hospital and at home. Intravenous (IV) therapy is the most performed invasive treatment with 3.8 bn disposables tubes used annually. This procedure is not safe, neither for healthcare personnel nor patients, with serious consequences such as accidental... ver más

30/09/2024

TADA MEDICAL AB

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

TADA MEDICAL AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-09-30

EIC-FTI-2018-2020: Fast Track to Innovation (FTI) Specific Challenge:

I+D

Cerrada hace 7 años

0% 75% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

TADA MEDICAL AB

1.05M€ | Lider

RIMSA METAL TECHNOLOGY

289.85K€ | Participante

GASGON MEDICAL

1.09M€ | Participante

PARC SANITARI SANT JOAN DE D...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 42 meses Fecha Inicio: 2021-03-08
Fecha Fin: 2024-09-30

Líder del proyecto

TADA MEDICAL AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Intravenous (IV) therapy is the most performed invasive treatment with 3.8 bn disposables tubes used annually. This procedure is not safe, neither for healthcare personnel nor patients, with serious consequences such as accidental IV dislodgement and Vascular Air Embolism (VAE) generating additional healthcare costs of €43b every year. In addition, there is a growing trend to administer IV infusion at home presenting social and economic benefits to patients with chronic diseases, cancer and, being especially important, to the current aging European population. In views of the situation, there is an urgent need for IV therapy risk reduction by preventing dislodgement, VAE and spill of hazardous fluids/vapours, while simultaneously supporting the ‘bringing care home initiative’. In response, we have developed ReAL, a weak-link tube connection and air removal devices that will make IV therapy more accurate and safer for healthcare personnel and patients by i) preventing accidental dislodgement, and ii) removing harmful air bubbles in a closed system,. ReAL helps patients to receive a more accurate dose with faster recovery, while healthcare providers save money. Providing IV therapy at home has shown a 90% potential cost saving compared to corresponding care provided in the hospital. In this SAFE-Infusion project we aim to disrupt the IV tube market by maturing, testing, and launching the next- generation tube connection and air removal device. Within the first five years post project, we estimate total accident-related cost-savings of €3.3bn for healthcare (i.e., €28 for each €1 spent in ReAL), 57 tonnes of plastic waste saved, €114m in accumulated revenues and €44m in accumulated operating profit for the SAFE-Infusion industry partners together.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores